Clonazepam
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Clonazepam: From Seizure Disorders to Restless Legs Syndrome
One-Sentence Summary
Clonazepam is a long-acting benzodiazepine historically used for seizure disorders and panic disorder. The TxGNN model predicts it may be effective for Restless Legs Syndrome, with 0 registered clinical trials but 20 supporting publications — including a Cochrane systematic review — currently available. A blocking gap in UK label safety data means this candidate cannot yet proceed past initial safety screening.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed in this evidence pack (data gap); clonazepam is internationally recognised as an anticonvulsant/anxiolytic benzodiazepine used for seizure disorders and panic disorder |
| Predicted New Indication | Restless Legs Syndrome |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack — the DrugBank query returned no MOA record. Based on general pharmacological knowledge, clonazepam is a long-acting benzodiazepine that binds the benzodiazepine site on the GABA-A receptor, enhancing GABAergic inhibitory neurotransmission across the central nervous system. This produces anticonvulsant, anxiolytic, sedative-hypnotic and skeletal-muscle-relaxant effects, and clonazepam has long been used clinically for seizure disorders and panic disorder.
Although this evidence pack does not record a confirmed licensed original indication for clonazepam, seizure disorders and panic disorder are both conditions of central nervous system hyperexcitability that respond to GABA-A potentiation — the same mechanism thought to underlie clonazepam’s effect in restless legs syndrome (RLS), a sensorimotor disorder characterised by an urge to move the legs, dysaesthesia, and disrupted sleep architecture.
Clonazepam has in fact been used off-label for RLS and periodic limb movement disorder for several decades, reflected in the literature evidence below, which spans from early placebo-controlled sleep-laboratory studies in the 1980s to a 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline. Its sedative and muscle-relaxant properties are thought to improve subjective sleep continuity in RLS, even though it does not directly address the dopaminergic/iron-related pathophysiology targeted by first-line agents (dopamine agonists, alpha-2-delta ligands). This positions clonazepam as a plausible adjunct or second-line option rather than a primary disease-modifying treatment — mechanistically reasonable, but requiring careful positioning relative to established therapies.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6380197 | 1984 | RCT | Acta Neurologica Scandinavica | Randomised double-blind placebo-controlled crossover trial (n=6) — clonazepam significantly improved subjective sleep quality and leg dysaesthesia in RLS; vibratory stimulation was less effective |
| 11313161 | 2001 | RCT | European Neuropsychopharmacology | Acute placebo-controlled sleep-laboratory study of 1 mg clonazepam in RLS/PLMD, assessing objective and subjective sleep/awakening quality against other drug classes |
| 31942156 | 2019 | RCT (open-label) | Journal of Mid-life Health | Prospective randomised study comparing clonazepam versus nortriptyline for RLS in women over 40 |
| 28319266 | 2017 | Systematic Review (Cochrane) | Cochrane Database of Systematic Reviews | Cochrane review of benzodiazepines, including clonazepam, for RLS; notes widespread clinical use despite limited high-quality trial evidence |
| 36692194 | 2023 | Systematic Review/Meta-analysis | Journal of Clinical Sleep Medicine | Systematic review and meta-analysis of pharmacological suppression of periodic limb movements across drug classes in RLS |
| 39324694 | 2025 | Clinical Practice Guideline | Journal of Clinical Sleep Medicine | AASM guideline establishing treatment recommendations for RLS and periodic limb movement disorder in adult and paediatric patients |
| 38708125 | 2024 | Review | Tremor and Other Hyperkinetic Movements | Historical overview of benzodiazepines, including clonazepam, in adult RLS/PLMS; ~25% of RLS patients in a 16,694-person survey received benzodiazepine therapy; reviews 17 clonazepam studies |
| 18925578 | 2008 | Review (MDS Task Force) | Movement Disorders | Evidence-based review of RLS treatment modalities, classifying therapeutic efficacy of each drug class |
| 24363103 | 2014 | Review | Neurotherapeutics | Overview of RLS treatment approaches and evolution of therapeutic options |
| 8572833 | 1996 | Review | Archives of Internal Medicine | General review of RLS presentation, epidemiology and treatment, including associations with iron deficiency, uraemia, pregnancy and diabetes |
UK Market Information
Clonazepam does not currently hold a UK marketing authorisation (MHRA) according to the regulatory data available in this evidence pack (0 licences on record; market status: not marketed). Prescribers should verify current BNF listing and any named-patient or unlicensed-import pathway with a specialist before considering use.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: safety data collection for this candidate is currently blocked — the UK/manufacturer label warnings and contraindications have not yet been retrieved (see Conclusion below), so this section cannot be considered complete.
Conclusion and Next Steps
Decision: Hold
Rationale:
- A blocking data gap exists: label warnings/contraindications have not been retrieved, so this candidate cannot yet pass initial safety screening (S1).
- Evidence for the restless legs syndrome indication is limited to observational data, small historical trials and a systematic review (Evidence Level L3) — there are no registered Phase 2/3 clinical trials for this indication.
- Clonazepam currently has no UK marketing authorisation, adding a regulatory access barrier alongside the clinical evidence gap.
To proceed, the following is needed:
- Retrieval of UK/manufacturer label warnings and contraindications to complete S1 safety screening
- Confirmed mechanism of action data from DrugBank
- Confirmation of clonazepam’s original licensed indication(s) and any existing UK access route (e.g. named-patient import)
- Review of the 2025 AASM guideline’s specific positioning of benzodiazepines (including clonazepam) relative to first-line RLS therapies
- A formal drug interaction (DDI) profile, currently unavailable (query status: not found)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.